Web Stats Provided By Google Analytics

Friday, July 21, 2017

Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent...

Sanofi and Regeneron Receive Positive CHMP Opinion for DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis Sanofi and Regeneron Receive Positive CHMP Opinion for DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis Paris, France and Tarrytown, N.Y. - July 21, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of DupixentA , recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
http://ift.tt/2gPIj7X

No comments:

Post a Comment

Popular Tarrytown Roundup Posts